PROTEO INC
PTEO evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Lead Asset:
- elafin (Preclinical)
What it means
What to watch
Prepared research question
What matters most for PTEO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
elafin (Preclinical)
Next Catalyst
—
Tracking 1 pipeline candidate for PROTEO INC.
Run PROTEO INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROTEO INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is PROTEO INC's lead drug candidate?
PROTEO INC's most advanced tracked candidate is elafin (Preclinical) for Pulmonary arterial hypertension.
Who is the CEO of PROTEO INC?
Oliver Wiedow is the chief executive officer of PROTEO INC (PTEO).
What therapeutic areas does PROTEO INC focus on?
PROTEO INC develops therapies across Cardiovascular, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.